HRP20120684T1 - Imunglobulini protiv nogo - Google Patents
Imunglobulini protiv nogo Download PDFInfo
- Publication number
- HRP20120684T1 HRP20120684T1 HRP20120684TT HRP20120684T HRP20120684T1 HR P20120684 T1 HRP20120684 T1 HR P20120684T1 HR P20120684T T HRP20120684T T HR P20120684TT HR P20120684 T HRP20120684 T HR P20120684T HR P20120684 T1 HRP20120684 T1 HR P20120684T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- host cell
- Prior art date
Links
- 108010077641 Nogo Proteins Proteins 0.000 title claims 4
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000010410 Nogo Proteins Human genes 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 239000012634 fragment Substances 0.000 claims abstract 5
- 239000013604 expression vector Substances 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 102100029831 Reticulon-4 Human genes 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Izolirano protutijelo, ili njegov fragment, koje se mo·e vezati na ljudski NOGO-A, naznačeno time ®to sadr·i varijabno područje te®kog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:49, te varijabno područje lakog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:14. Patent sadr·i jo® 10 patentnih zahtjeva.
Claims (11)
1. Izolirano protutijelo, ili njegov fragment, koje se može vezati na ljudski NOGO-A, naznačeno time što sadrži varijabno područje teškog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:49, te varijabno područje lakog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:14.
2. Izolirano protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što ima teški lanac, čiji je aminokiselinski slijed iznijet u SEQ ID NO:55, te laki lanac, čiji je aminokiselinski slijed iznijet u SEQ ID NO:18.
3. Ekspresijski vektor, naznačen time što sadrži polinukleotidne sljedove koji kodiraju protutijelo u skladu s patentnim zahtjevom 1 ili 2.
4. Stanica-domaćin, naznačena time što sadrži ekspresijski vektor u skladu s patentnim zahtjevom 3.
5. Stanica-domaćin u skladu s patentnim zahtjevom 4, naznačena time što navedena stanica sadrži prvi vektor koji kodira laki lanac i drugi vektor koji kodira teški lanac.
6. Postupak proizvodnje protutijela koje se može vezati na ljudski NOGO-A, naznačen time što se navedeni postupak sastoji u koracima: transficiranja stanice-domaćina ekspresijskim vektorom koji sadrži prvi polinukleotid, koji kodira varijabno područje teškog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:49, i ekspresijski vektor koji sadrži drugi polinukleotid, koji kodira varijabno područje lakog lanca, čiji je aminokiselinski slijed iznijet u SEQ ID NO:14, te uzgoja stanice-domaćina u uvjetima pogodnim za izlučivanje protutijela iz navedene stanice-domaćina u navedenom mediju za kulturu.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što dodatno uključuje korak izdvajanja izlučenog protutijela iz medija za kulturu.
8. Postupak u skladu s patentnim zahtjevom 6 ili 7, naznačen time što se i prvi i drugi polinukleotid nalaze u istom ekspresijskom vektoru.
9. Farmaceutski pripravak, naznačen time što sadrži protutijelo protiv NOGO, ili njegov fragment, u skladu s patentnim zahtjevom 1 ili 2, uz farmaceutski prihvatljiv razrjeđivač ili podlogu.
10. Upotreba protutijela protiv NOGO, ili njegovog fragmenta, u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je navedeno protutijelo, ili njegov fragment, namijenjeno pripravi medikamenta za liječenje ili profilaksu inzulta i drugih neuroloških bolesti odnosno poremećaja ili za liječenje pacijenta koji boluje od mehaničke traume središnjeg ili perifernog živčanog sustava.
11. Protutijelo protiv NOGO u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što je namijenjeno upotrebi u liječenju ili profilaksi inzulta i drugih neuroloških bolesti odnosno poremećaja ili liječenju pacijenta koji boluje od mehaničke traume središnjeg ili perifernog živčanog sustava.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0525662.3A GB0525662D0 (en) | 2005-12-16 | 2005-12-16 | Immunoglobulins |
| PCT/EP2006/069737 WO2007068750A2 (en) | 2005-12-16 | 2006-12-14 | Immunoglobulins directed against nogo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120684T1 true HRP20120684T1 (hr) | 2012-09-30 |
Family
ID=35736284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120684TT HRP20120684T1 (hr) | 2005-12-16 | 2012-08-29 | Imunglobulini protiv nogo |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8362208B2 (hr) |
| EP (2) | EP1960429B1 (hr) |
| JP (1) | JP5015949B2 (hr) |
| KR (1) | KR101355118B1 (hr) |
| CN (1) | CN101374863B (hr) |
| AR (1) | AR057239A1 (hr) |
| AU (1) | AU2006325228B2 (hr) |
| BR (1) | BRPI0619855A2 (hr) |
| CA (1) | CA2633501C (hr) |
| CR (1) | CR10099A (hr) |
| CY (1) | CY1113094T1 (hr) |
| DK (1) | DK1960429T3 (hr) |
| EA (1) | EA015536B1 (hr) |
| ES (1) | ES2389380T3 (hr) |
| GB (1) | GB0525662D0 (hr) |
| HK (1) | HK1119720A1 (hr) |
| HR (1) | HRP20120684T1 (hr) |
| IL (1) | IL192086A0 (hr) |
| JO (1) | JO2795B1 (hr) |
| MA (1) | MA30041B1 (hr) |
| MY (1) | MY149492A (hr) |
| NO (1) | NO20082699L (hr) |
| NZ (1) | NZ569143A (hr) |
| PE (1) | PE20071099A1 (hr) |
| PL (1) | PL1960429T3 (hr) |
| PT (1) | PT1960429E (hr) |
| SI (1) | SI1960429T1 (hr) |
| TW (1) | TWI378940B (hr) |
| UA (1) | UA96279C2 (hr) |
| WO (1) | WO2007068750A2 (hr) |
| ZA (2) | ZA200805111B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009258063B2 (en) | 2007-06-21 | 2014-09-25 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| WO2009056509A1 (en) | 2007-11-02 | 2009-05-07 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use thereof |
| UY31807A (es) | 2008-05-06 | 2009-12-14 | Glaxo Group Ltd | Encapsulación de agentes biológicamente activos |
| WO2010004031A2 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| EP2870177A1 (en) | 2012-07-05 | 2015-05-13 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| WO2018232144A1 (en) * | 2017-06-14 | 2018-12-20 | Monojul, Llc | High-affinity anti-human folate receptor beta antibodies and methods of use |
| CN114599676A (zh) | 2019-10-24 | 2022-06-07 | 诺华康制药股份公司 | 新型抗-Nogo-A抗体 |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| WO2022263864A1 (en) | 2021-06-17 | 2022-12-22 | Petmedix Ltd | Anti canine cd20 antibodies |
| WO2023067358A1 (en) | 2021-10-21 | 2023-04-27 | Petmedix Ltd | Proteins comprising the extracellular domain of p75ntr |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| WO2023152486A1 (en) | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| ATE273959T1 (de) | 1994-05-27 | 2004-09-15 | Glaxosmithkline Spa | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| WO1997001352A1 (en) | 1995-06-27 | 1997-01-16 | Research Foundation Of Cuny, Hunter College | Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| DE69942803D1 (de) | 1998-07-22 | 2010-11-11 | Smithkline Beecham Ltd | Rotein änhelt, und dafür kodierende cdns |
| MXPA01004598A (es) | 1998-11-06 | 2002-04-24 | Martin E Schwab | Secuencias de nucleotidos y proteinas de los genes nogo y metodos basados en estas. |
| FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| DE10338136A1 (de) | 2003-08-15 | 2005-03-24 | European Molecular Biology Laboratory | Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| SI1711530T1 (sl) * | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni |
| EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US7973139B2 (en) * | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
-
2005
- 2005-12-16 GB GBGB0525662.3A patent/GB0525662D0/en not_active Ceased
-
2006
- 2006-12-14 AR ARP060105524A patent/AR057239A1/es active IP Right Grant
- 2006-12-14 EP EP06830633A patent/EP1960429B1/en active Active
- 2006-12-14 CA CA2633501A patent/CA2633501C/en not_active Expired - Fee Related
- 2006-12-14 EA EA200801343A patent/EA015536B1/ru not_active IP Right Cessation
- 2006-12-14 JP JP2008545009A patent/JP5015949B2/ja not_active Expired - Fee Related
- 2006-12-14 UA UAA200807663A patent/UA96279C2/ru unknown
- 2006-12-14 EP EP20100162457 patent/EP2228391A3/en not_active Withdrawn
- 2006-12-14 PL PL06830633T patent/PL1960429T3/pl unknown
- 2006-12-14 PE PE2006001607A patent/PE20071099A1/es not_active Application Discontinuation
- 2006-12-14 DK DK06830633.1T patent/DK1960429T3/da active
- 2006-12-14 NZ NZ569143A patent/NZ569143A/en not_active IP Right Cessation
- 2006-12-14 WO PCT/EP2006/069737 patent/WO2007068750A2/en active Application Filing
- 2006-12-14 SI SI200631393T patent/SI1960429T1/sl unknown
- 2006-12-14 BR BRPI0619855-4A patent/BRPI0619855A2/pt not_active IP Right Cessation
- 2006-12-14 US US12/097,279 patent/US8362208B2/en not_active Expired - Fee Related
- 2006-12-14 PT PT06830633T patent/PT1960429E/pt unknown
- 2006-12-14 ES ES06830633T patent/ES2389380T3/es active Active
- 2006-12-14 AU AU2006325228A patent/AU2006325228B2/en not_active Ceased
- 2006-12-14 MY MYPI20082130A patent/MY149492A/en unknown
- 2006-12-14 CN CN2006800529521A patent/CN101374863B/zh not_active Expired - Fee Related
- 2006-12-14 KR KR1020087017348A patent/KR101355118B1/ko not_active IP Right Cessation
- 2006-12-14 TW TW095146890A patent/TWI378940B/zh not_active IP Right Cessation
- 2006-12-24 JO JO2006457A patent/JO2795B1/en active
-
2008
- 2008-06-11 ZA ZA200805111A patent/ZA200805111B/xx unknown
- 2008-06-11 MA MA31018A patent/MA30041B1/fr unknown
- 2008-06-11 NO NO20082699A patent/NO20082699L/no not_active Application Discontinuation
- 2008-06-12 IL IL192086A patent/IL192086A0/en not_active IP Right Cessation
- 2008-06-20 CR CR10099A patent/CR10099A/es unknown
- 2008-12-08 HK HK08113307.3A patent/HK1119720A1/xx not_active IP Right Cessation
-
2009
- 2009-09-04 ZA ZA200906162A patent/ZA200906162B/en unknown
-
2012
- 2012-08-29 HR HRP20120684TT patent/HRP20120684T1/hr unknown
- 2012-09-05 CY CY20121100801T patent/CY1113094T1/el unknown
-
2013
- 2013-01-28 US US13/751,588 patent/US20130287781A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120684T1 (hr) | Imunglobulini protiv nogo | |
| US9828423B2 (en) | Anti-BLyS antibody | |
| Bitzan et al. | TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation | |
| JP5828916B2 (ja) | 幹細胞のインビボ移動誘導方法 | |
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| JP2022513383A (ja) | 二重特異性抗体及びその作製方法と使用 | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| ES2556630T3 (es) | Medio condicionado para células progenitoras de hígado | |
| RU2009118621A (ru) | Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний | |
| JP2015501134A5 (hr) | ||
| CN106046166A (zh) | 结合人蛋白酪氨酸磷酸酶β(HPTPβ)的抗体及其用途 | |
| CN107595889A (zh) | 缺血性组织的细胞疗法 | |
| RU2010145063A (ru) | Новые антитела, используемые для лечения рака | |
| WO2020156222A1 (zh) | 人源化抗Aβ单克隆抗体及其应用 | |
| JP2020073503A (ja) | タンパク質産生方法 | |
| CN103936854A (zh) | 抗il-17a单克隆抗体及其制备与应用 | |
| US10329350B2 (en) | Method for producing a multivalent fab fragment with collagen-like peptide | |
| WO2022166802A1 (zh) | 抗人cd271的单克隆抗体及用途 | |
| CN106459190A (zh) | 用于治疗疼痛的化合物和方法 | |
| Tian et al. | Fecal microbiota transplantation enhances cell therapy in a rat model of hypoganglionosis by SCFA‐induced MEK1/2 signaling pathway | |
| Mehta et al. | Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: Targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis | |
| RU2017134042A (ru) | ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ | |
| WO2020156221A1 (zh) | 人源化抗Aβ单克隆抗体及其应用 | |
| CN112725268A (zh) | 一种促进脂肪干细胞成骨分化的组合物及其应用 | |
| CN105916883A (zh) | 双功能融合蛋白及其制备方法和用途 |